These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21673660)

  • 21. Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses-Clearance and Biodistribution in Naïve and HSV-Preimmune Mice.
    Vannini A; Parenti F; Barboni C; Forghieri C; Leoni V; Sanapo M; Bressanin D; Zaghini A; Campadelli-Fiume G; Gianni T
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors.
    Muraro E; Vinante L; Fratta E; Bearz A; Höfler D; Steffan A; Baboci L
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emerging field of oncolytic virus-based cancer immunotherapy.
    Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
    Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma.
    Toulmonde M; Cousin S; Kind M; Guegan JP; Bessede A; Le Loarer F; Perret R; Cantarel C; Bellera C; Italiano A
    J Hematol Oncol; 2022 Oct; 15(1):149. PubMed ID: 36271420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant Oncolytic Adenovirus Combined with Cyclophosphamide Induces Synergy in the Treatment of Breast Cancer in vitro and in vivo.
    Wang J; Zuo S; Zhang Y; Li S; Shi Y; Du T; Han J; Jin N; Li Y; Li X
    Cancer Manag Res; 2022; 14():2749-2761. PubMed ID: 36133740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Senecavirus A as an Oncolytic Virus: Prospects, Challenges and Development Directions.
    Luo D; Wang H; Wang Q; Liang W; Liu B; Xue D; Yang Y; Ma B
    Front Oncol; 2022; 12():839536. PubMed ID: 35371972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in Immunotherapies for Gliomas.
    Zhang M; Choi J; Lim M
    Curr Neurol Neurosci Rep; 2022 Jan; 22(1):1-10. PubMed ID: 35107784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Trials of Oncolytic Viruses in Breast Cancer.
    Carter ME; Koch A; Lauer UM; Hartkopf AD
    Front Oncol; 2021; 11():803050. PubMed ID: 35004328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors.
    Pierce KM; Miklavcic WR; Cook KP; Hennen MS; Bayles KW; Hollingsworth MA; Brooks AE; Pullan JE; Dailey KM
    Nanomaterials (Basel); 2021 Nov; 11(11):. PubMed ID: 34835785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic analysis on the clinical safety and efficacy of onco-virotherapy.
    Bhatt DK; Wekema L; Carvalho Barros LR; Chammas R; Daemen T
    Mol Ther Oncolytics; 2021 Dec; 23():239-253. PubMed ID: 34761104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Harnessing the Immune System to Fight Multiple Myeloma.
    Krejcik J; Barnkob MB; Nyvold CG; Larsen TS; Barington T; Abildgaard N
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
    Hofman L; Lawler SE; Lamfers MLM
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
    Wu W; Klockow JL; Zhang M; Lafortune F; Chang E; Jin L; Wu Y; Daldrup-Link HE
    Pharmacol Res; 2021 Sep; 171():105780. PubMed ID: 34302977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits.
    Spiesschaert B; Angerer K; Park J; Wollmann G
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy.
    Mu W; Chu Q; Liu Y; Zhang N
    Nanomicro Lett; 2020 Jul; 12(1):142. PubMed ID: 34138136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
    Zhang S; Rabkin SD
    Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical Application of Oncolytic Viruses: A Systematic Review.
    Cook M; Chauhan A
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene.
    Chiocca EA; Nakashima H; Kasai K; Fernandez SA; Oglesbee M
    Mol Ther Methods Clin Dev; 2020 Jun; 17():871-893. PubMed ID: 32373649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway.
    Zhong H; Lai Y; Zhang R; Daoud A; Feng Q; Zhou J; Shang J
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses.
    Hoare J; Campbell N; Carapuça E
    Porto Biomed J; 2018 Aug; 3(1):e7. PubMed ID: 31595233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.